Catabasis Pharmaceuticals Stock Forecast, Price & News

Catabasis Pharmaceuticals (NASDAQ:ATXS) Frequently Asked Questions

Is Catabasis Pharmaceuticals a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catabasis Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Catabasis Pharmaceuticals stock.
View analyst ratings for Catabasis Pharmaceuticals or view top-rated stocks.

How has Catabasis Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Catabasis Pharmaceuticals' stock was trading at $26.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ATXS shares have decreased by 81.9% and is now trading at $4.83.
View which stocks have been most impacted by COVID-19.

When is Catabasis Pharmaceuticals' next earnings date?

Catabasis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Catabasis Pharmaceuticals.

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals, Inc. (NASDAQ:ATXS) announced its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.61) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.92) by $0.31. During the same period in the previous year, the company earned ($3.36) earnings per share.
View Catabasis Pharmaceuticals' earnings history.

When did Catabasis Pharmaceuticals' stock split? How did Catabasis Pharmaceuticals' stock split work?

Catabasis Pharmaceuticals's stock reverse split before market open on Friday, August 20th 2021. The 1-6 reverse split was announced on Friday, August 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 20th 2021. An investor that had 100 shares of Catabasis Pharmaceuticals stock prior to the reverse split would have 17 shares after the split.

What price target have analysts set for ATXS?

5 brokerages have issued 1 year target prices for Catabasis Pharmaceuticals' stock. Their forecasts range from $13.00 to $36.00. On average, they anticipate Catabasis Pharmaceuticals' share price to reach $23.00 in the next twelve months. This suggests a possible upside of 376.2% from the stock's current price.
View analysts' price targets for Catabasis Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Catabasis Pharmaceuticals' key executives?

Catabasis Pharmaceuticals' management team includes the following people:

• Jill C. Milne, President, Chief Executive Officer & Director
• Noah Clauser, Chief Financial Officer
• Maria C. Mancini, Vice President-Clinical Operations
• Andrew Nichols, Chief Scientific Officer
• Andrew A. Komjathy, Chief Commercial Officer

Who are some of Catabasis Pharmaceuticals' key competitors?

Some companies that are related to Catabasis Pharmaceuticals include Provention Bio (PRVB), Enochian Biosciences (ENOB), MEI Pharma (MEIP), Alpine Immune Sciences (ALPN), Pieris Pharmaceuticals (PIRS), Immutep (IMMP), XOMA (XOMA), Rain Therapeutics (RAIN), Olema Pharmaceuticals (OLMA), KemPharm (KMPH), Theratechnologies (THERF), Antibe Therapeutics (ATBPD), Capstar Special Purpose Acquisition (CPSR), Epizyme (EPZM) and Citius Pharmaceuticals (CTXR).
View all of ATXS's competitors.

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ATXS."

How do I buy shares of Catabasis Pharmaceuticals?

Shares of ATXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catabasis Pharmaceuticals' stock price today?

One share of ATXS stock can currently be purchased for approximately $4.83.

How much money does Catabasis Pharmaceuticals make?

Catabasis Pharmaceuticals has a market capitalization of $62.83 million. The biotechnology company earns $-37.30 million in net income (profit) each year or ($54.2394) on an earnings per share basis.

How many employees does Catabasis Pharmaceuticals have?

Catabasis Pharmaceuticals employs 20 workers across the globe.

What is Catabasis Pharmaceuticals' official website?

The official website for Catabasis Pharmaceuticals is www.catabasis.com.

Where are Catabasis Pharmaceuticals' headquarters?

Catabasis Pharmaceuticals is headquartered at 100 High StreetFloor 28, Boston MA, 02110.

How can I contact Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals' mailing address is 100 High StreetFloor 28, Boston MA, 02110. The biotechnology company can be reached via phone at (617) 349-1971, via email at [email protected], or via fax at 617-273-2637.